These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29877131)

  • 41. OnabotulinumtoxinA in pediatric chronic daily headache.
    Kabbouche M; O'Brien H; Hershey AD
    Curr Neurol Neurosci Rep; 2012 Apr; 12(2):114-7. PubMed ID: 22274570
    [TBL] [Abstract][Full Text] [Related]  

  • 42. OnabotulinumtoxinA in chronic migraine: long-term efficacy in a prophylactic medication free cohort.
    Schiano di Cola F; Pari E; Caratozzolo S; Mancinelli C; Liberini P; Rao R; Padovani A
    Neurol Sci; 2018 Jun; 39(Suppl 1):159-160. PubMed ID: 29904848
    [No Abstract]   [Full Text] [Related]  

  • 43. Migraine prophylaxis with botulinum toxin A is associated with perception of headache.
    Burstein R; Dodick D; Silberstein S
    Toxicon; 2009 Oct; 54(5):624-7. PubMed ID: 19344670
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Corasaniti MT; Bagetta G; Nicotera P; Tarsitano A; Tonin P; Sandrini G; Lawrence GW; Scuteri D
    Toxins (Basel); 2023 May; 15(5):. PubMed ID: 37235366
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience.
    Farinelli I; Coloprisco G; De Filippis S; Martelletti P
    J Headache Pain; 2006 Dec; 7(6):407-12. PubMed ID: 17149565
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Method of onabotulinumtoxin type A injection in chronic migraine: the PREEMPT protocol in clinical practice].
    Latysheva NV; Naprienko MV; Filatova EG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(8):93-96. PubMed ID: 34481443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database.
    Hepp Z; Rosen NL; Gillard PG; Varon SF; Mathew N; Dodick DW
    Cephalalgia; 2016 Aug; 36(9):862-74. PubMed ID: 26692400
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Botulinum neurotoxin A for chronic migraine headaches: does it work and how?
    Cairns BE; Gazerani P
    Pain Manag; 2014; 4(6):377-80. PubMed ID: 25494688
    [No Abstract]   [Full Text] [Related]  

  • 49. OnabotulinumtoxinA wear-off in chronic migraine, observational cohort study.
    Zidan A; Roe C; Burke D; Mejico L
    J Clin Neurosci; 2019 Nov; 69():237-240. PubMed ID: 31327585
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is Botox Right for Me: When to Assess the Efficacy of the Botox Injection for Chronic Migraine in Pediatric Population.
    Goenka A; Yu SG; George MC; Chikkannaiah M; MacDonald S; Stolfi A; Kumar G
    Neuropediatrics; 2022 Oct; 53(5):344-350. PubMed ID: 35453165
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Botulinum Toxin for Pediatric Migraine: A Retrospective Multisite Cohort Study.
    Horvat DE; Shields JM; Young WWC; Eye PG
    Pediatr Neurol; 2023 Oct; 147():68-71. PubMed ID: 37562172
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
    Blumenfeld AM; Schim JD; Chippendale TJ
    Headache; 2008 Feb; 48(2):210-20. PubMed ID: 18047502
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Onabotulinumtoxina in the Prevention of Migraine in Pediatric Population: A Systematic Review.
    Mavridi A; Redmond A; Archontakis-Barakakis P; Bogdanova-Mihaylova P; Deligianni CI; Mitsikostas DD; Mavridis T
    Toxins (Basel); 2024 Jun; 16(7):. PubMed ID: 39057935
    [TBL] [Abstract][Full Text] [Related]  

  • 54. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
    Lipton RB; Varon SF; Grosberg B; McAllister PJ; Freitag F; Aurora SK; Dodick DW; Silberstein SD; Diener HC; DeGryse RE; Nolan ME; Turkel CC
    Neurology; 2011 Oct; 77(15):1465-72. PubMed ID: 21956721
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine.
    Gómez-Dabó L; Caronna E; Mas-de-Les-Valls R; Gallardo VJ; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
    Toxins (Basel); 2024 May; 16(5):. PubMed ID: 38787073
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Botulinum toxin type A for preventive treatment of chronic migraines].
    Göbel H; Heinze A
    HNO; 2012 Jun; 60(6):490-5. PubMed ID: 22669437
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dispute settlement understanding on the use of Botox in chronic migraine.
    Martelletti P
    J Headache Pain; 2011 Feb; 12(1):1-2. PubMed ID: 21246242
    [No Abstract]   [Full Text] [Related]  

  • 58. Onabotulinumtoxin A for prophylaxis in chronic migraine: preliminary data from Headache Regional Centre of Aosta Valley.
    Lia C; Tosi P; Giardini G; Caligiana L; Bottacchi E
    Neurol Sci; 2014 May; 35 Suppl 1():175-6. PubMed ID: 24867860
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Generalized Anxiety Disorder: A Predictor for Poor Responsiveness to Botulinum Toxin Type A Therapy for Pediatric Migraine.
    Goenka A; Grace Yu S; Chikkannaiah M; George MC; MacDonald S; Stolfi A; Kumar G
    Pediatr Neurol; 2022 May; 130():21-27. PubMed ID: 35305510
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.